search
Back to results

Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke (BEST-BAO)

Primary Purpose

Acute Ischemic Stroke, Basilar Artery Occlusion, Thrombosis

Status
Not yet recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Endovascular treatment
Intravenous thrombolysis (Alteplase)
Sponsored by
Sichuan Academy of Medical Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Ischemic Stroke focused on measuring Endovascular treatment, Alteplase, Acute ischemic stroke, Basilar artery occlusion, Intravenous thrombosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: A clinical diagnosis of acute ischemic stroke (AIS); Caused by basilar artery occlusion (BAO) confirmed by CTA, MRA, or DSA; CT or MRI ruling out intracranial hemorrhage; Eligible for intravenous thrombolysis (IVT) and endovascular treatment (EVT) (within 4.5 hours after symptom onset); A score of at least 6 on the NIHSS score; Age of 18 years or older; Written informed consent. Exclusion Criteria: Pre-stroke disability which interferes with the assessment of functional outcome at 90 days, i.e. mRS >2 Any contra-indication for intravenous thrombolysis (IVT), according to guidelines of the American Heart Association, i.e.: Arterial blood pressure exceeding 185/110 mmHg Blood glucose less than 2.7 or over 22.2 mmol/L Cerebral infarction in the previous 6 weeks with residual neurological deficit or signs of recent infarction on neuro-imaging Serious head trauma in the previous 3 months Major surgery or serious trauma in the previous 2 weeks Gastrointestinal or urinary tract hemorrhage in the previous 3 weeks Previous intracerebral hemorrhage Use of anticoagulant with INR exceeding 1.7 Known thrombocyte count less than 100 x 10^9/L Treatment with direct thrombin or factor X inhibitors Treatment with heparin (APTT exceeds the upper limit of normal value) in the previous 48 hours.

Sites / Locations

  • The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
  • Banan Hospital Affiliated to Chongqing Medical University
  • Chongqing Sanbo Chang'an Hospital
  • Hechuan District People's Hospital
  • Liangping District People's Hospital
  • The First People's Hospital of Liangjiang New Area
  • Yubei District People's Hospital
  • The Fifth People's Hospital Affiliated to Southern Medical University
  • Qiandongnan Miao and Dong Autonomous Prefecture People's Hospital
  • Tongren People's Hospital
  • Qianxinan Buyei and Miao Autonomous Prefecture People's Hospital
  • Nanyang Central Hospital
  • Zhuzhou Central Hospital
  • Bazhong Central Hospital
  • Chengdu Third People's Hospital
  • Affiliated Hospital of Chengdu Medical College
  • Chengdu Fifth People's Hospital
  • Chengdu First People's Hospital
  • Chengdu Second People's Hospital
  • Chongzhou People's Hospital
  • Dayi County People's Hospital
  • Western Theater General Hospital
  • Deyang People's Hospital
  • Guang'an Central Hospital
  • Guangyuan Central Hospital
  • Guangyuan First People's Hospital
  • Affiliated Hospital of Southwest Medical University
  • Mianyang 404 Hospital
  • Mianyang Central Hospital
  • Mianyang Third People's Hospital
  • Affiliated Hospital of North Sichuan Medical College
  • Langzhong People's Hospital
  • Nanchong Central Hospital
  • Yilong County People's Hospital
  • Neijiang Second People's Hospital
  • Panzhihua Central Hospital
  • Suining Central Hospital
  • Suining First People's Hospital
  • Ya'an People's Hospital
  • Yibin First People's Hospital
  • Yibin Second People's Hospital
  • Zigong First People's Hospital
  • Zigong Third People's Hospital
  • Ziyang First People's Hospital
  • Kashgar First People's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Sham Comparator

Active Comparator

Arm Label

Direct endovascular treatment group

Bridging treatment group

Arm Description

Direct endovascular treatment (EVT) without intravenous thrombolysis (IVT)

Intravenous thrombolysis (IVT) followed by endovascular treatment (EVT)

Outcomes

Primary Outcome Measures

mRS (the modified Rankin Scale) score
The mRS score is an ordinal hierarchical scale ranging from 0 to 5, with higher scores suggesting more severe disability.

Secondary Outcome Measures

NIHSS (the National Institutes of Health Stroke Scale) score
The NIHSS score is an ordinal hierarchical scale to evaluate the symptomatic severity of stroke by assessing a patient's performance. Scores range from 0 to 42, with higher scores suggesting a more severe deficit.
Recanalization rate
The recanalization rate at 24-72 hours after endovascular treatment, assessed by computerized tomographic angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA).
Final infarct volume
The final infarct volume will be assessed with the use of an automated, validated algorithm based on magnetic resource imaging test.
All-cause mortality
The proportion of total deaths caused by various reasons in both arms
eTICI (Extended Treatment In Cerebral Ischemia) score
The eTICI is an ordinal hierarchical scale ranging from 0 to 3, with higher scores suggesting better antegrade reperfusion of the previously occluded target artery ischemic territory.
sICH (symptomatic intracranial hemorrhage) rate
The sICH means any hemorrhage with neurological deterioration, as indicated by an NIHSS score that was higher by ≥4 points than the value at baseline or the lowest value in the first 7 days or any hemorrhage leading to death.
Comparison of mRS 0-1 and mRS 2-6
The mRS score is an ordinal hierarchical scale ranging from 0 to 5, with higher scores suggesting more severe disability.
Comparison of mRS 0-2 and mRS 3-6
The mRS score is an ordinal hierarchical scale ranging from 0 to 5, with higher scores suggesting more severe disability.
Comparison of mRS 0-3 and mRS 4-6
The mRS score is an ordinal hierarchical scale ranging from 0 to 5, with higher scores suggesting more severe disability.
EQ-5D-5L (the European Quality of Life 5-Dimension 5-Level) score
The EQ-5D-5L score is an ordinal hierarchical scale to evaluate the quality of life. Scores range from -0.39 to 1, with higher scores indicating a better quality of life.
Barthel Index
dichotomized as 0 to 94 The Barthel Index is an ordinal hierarchical scale to evaluate the daily activities. Scores range from 0 to 100. The Barthel Index will be dichotomized as 0 to 94 vs. 95 to 100, with a score of 95 to 100 indicating no interference with daily activities.
Proportion of new cerebral infarction
The proportion of the new cerebral infarction compared with the onset of symptoms evaluated with magnetic resource imaging test
Incidence of pseudoaneurysm at puncture site
The pseudoaneurysm at puncture site caused by various reasons is one of the important indicators reflecting puncture complications.
Incidence of hematoma at puncture site
The hematoma at puncture site caused by various reasons is one of the important indicators reflecting puncture complications.

Full Information

First Posted
November 20, 2022
Last Updated
November 29, 2022
Sponsor
Sichuan Academy of Medical Sciences
Collaborators
Sichuan Provincial People's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05631847
Brief Title
Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke
Acronym
BEST-BAO
Official Title
Endovascular Treatment With Or Without Intravenous Alteplase In Acute Ischemic Stroke Of Basilar Artery Occlusion: A Multicenter, Prospective, Randomized Controlled Trial (BEST-BAO)
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 15, 2023 (Anticipated)
Primary Completion Date
January 15, 2027 (Anticipated)
Study Completion Date
May 31, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sichuan Academy of Medical Sciences
Collaborators
Sichuan Provincial People's Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Two recent randomized controlled trials (BAOCHE and ATTENTION) have confirmed the efficacy and safety of endovascular therapy in patient with acute ischemic stroke (AIS) due to basilar artery occlusion (BAO). However, it is still inconclusive whether there is any differences between endovascular therapy with or without bridging intravenous thrombolysis in acute BAO. So far, no randomized controlled trial has been conducted specifically for endovascular therapy with or without intravenous thrombolysis for ischemic stroke due to BAO. Therefore, this study plans to conduct a prospective, multicenter, randomized controlled trial to compare the functional outcomes between endovascular therapy with and without intravenous thrombolysis in patient with AIS due to BAO. This study is a multicenter, parallel, open label, randomized controlled trial comparing direct endovascular therapy versus endovascular therapy bridging intravenous thrombolysis (IVT). This study intends to include patients with AIS due to BAO fulfilling the following inclusion criteria: patients with AIS caused by BAO confirmed by CTA/MRA/DSA; IVT can be started within 4.5 hours after symptoms onset; Age ≥ 18 years old; NIHSS score ≥ 6. The main outcome is the 3-month mRS scale score. Secondary outcomes included NIHSS at 24 hours and 7 days after surgery, CTA vascular recanalization at 24-72 hours, mRS at 5-7 days, and infarct volume. The safety outcomes included 90-day mortality and the incidence of sICH.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Ischemic Stroke, Basilar Artery Occlusion, Thrombosis, Alteplase, Endovascular Treatment
Keywords
Endovascular treatment, Alteplase, Acute ischemic stroke, Basilar artery occlusion, Intravenous thrombosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
336 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Direct endovascular treatment group
Arm Type
Sham Comparator
Arm Description
Direct endovascular treatment (EVT) without intravenous thrombolysis (IVT)
Arm Title
Bridging treatment group
Arm Type
Active Comparator
Arm Description
Intravenous thrombolysis (IVT) followed by endovascular treatment (EVT)
Intervention Type
Procedure
Intervention Name(s)
Endovascular treatment
Intervention Description
It is the emergency surgical removal of emboli which are blocking blood circulation. The strategies that were used for endovascular treatment included stent retrievers, thromboaspiration, balloon angioplasty, stent deployment, intraarterial thrombolysis (with alteplase), or combinations of these approaches that were left to the discretion of the treating team.
Intervention Type
Drug
Intervention Name(s)
Intravenous thrombolysis (Alteplase)
Intervention Description
Alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
Primary Outcome Measure Information:
Title
mRS (the modified Rankin Scale) score
Description
The mRS score is an ordinal hierarchical scale ranging from 0 to 5, with higher scores suggesting more severe disability.
Time Frame
At 90 day after procedure
Secondary Outcome Measure Information:
Title
NIHSS (the National Institutes of Health Stroke Scale) score
Description
The NIHSS score is an ordinal hierarchical scale to evaluate the symptomatic severity of stroke by assessing a patient's performance. Scores range from 0 to 42, with higher scores suggesting a more severe deficit.
Time Frame
At 24 hours and 5-7 days after procedure
Title
Recanalization rate
Description
The recanalization rate at 24-72 hours after endovascular treatment, assessed by computerized tomographic angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA).
Time Frame
At 24-48 hours after endovascular treatment
Title
Final infarct volume
Description
The final infarct volume will be assessed with the use of an automated, validated algorithm based on magnetic resource imaging test.
Time Frame
At 5-7 days after procedure
Title
All-cause mortality
Description
The proportion of total deaths caused by various reasons in both arms
Time Frame
At 90 days after procedure
Title
eTICI (Extended Treatment In Cerebral Ischemia) score
Description
The eTICI is an ordinal hierarchical scale ranging from 0 to 3, with higher scores suggesting better antegrade reperfusion of the previously occluded target artery ischemic territory.
Time Frame
Immediately after endovascular treatment
Title
sICH (symptomatic intracranial hemorrhage) rate
Description
The sICH means any hemorrhage with neurological deterioration, as indicated by an NIHSS score that was higher by ≥4 points than the value at baseline or the lowest value in the first 7 days or any hemorrhage leading to death.
Time Frame
At 7 days after endovascular treatment
Title
Comparison of mRS 0-1 and mRS 2-6
Description
The mRS score is an ordinal hierarchical scale ranging from 0 to 5, with higher scores suggesting more severe disability.
Time Frame
At 90 days after procedure
Title
Comparison of mRS 0-2 and mRS 3-6
Description
The mRS score is an ordinal hierarchical scale ranging from 0 to 5, with higher scores suggesting more severe disability.
Time Frame
At 90 days after procedure
Title
Comparison of mRS 0-3 and mRS 4-6
Description
The mRS score is an ordinal hierarchical scale ranging from 0 to 5, with higher scores suggesting more severe disability.
Time Frame
At 90 days after procedure
Title
EQ-5D-5L (the European Quality of Life 5-Dimension 5-Level) score
Description
The EQ-5D-5L score is an ordinal hierarchical scale to evaluate the quality of life. Scores range from -0.39 to 1, with higher scores indicating a better quality of life.
Time Frame
At 90 days after procedure
Title
Barthel Index
Description
dichotomized as 0 to 94 The Barthel Index is an ordinal hierarchical scale to evaluate the daily activities. Scores range from 0 to 100. The Barthel Index will be dichotomized as 0 to 94 vs. 95 to 100, with a score of 95 to 100 indicating no interference with daily activities.
Time Frame
At 90 days after procedure
Title
Proportion of new cerebral infarction
Description
The proportion of the new cerebral infarction compared with the onset of symptoms evaluated with magnetic resource imaging test
Time Frame
At 5-7 days after procedure
Title
Incidence of pseudoaneurysm at puncture site
Description
The pseudoaneurysm at puncture site caused by various reasons is one of the important indicators reflecting puncture complications.
Time Frame
At 5-7 days after procedure
Title
Incidence of hematoma at puncture site
Description
The hematoma at puncture site caused by various reasons is one of the important indicators reflecting puncture complications.
Time Frame
At 5-7 days after procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A clinical diagnosis of acute ischemic stroke (AIS); Caused by basilar artery occlusion (BAO) confirmed by CTA, MRA, or DSA; CT or MRI ruling out intracranial hemorrhage; Eligible for intravenous thrombolysis (IVT) and endovascular treatment (EVT) (within 4.5 hours after symptom onset); A score of at least 6 on the NIHSS score; Age of 18 years or older; Written informed consent. Exclusion Criteria: Pre-stroke disability which interferes with the assessment of functional outcome at 90 days, i.e. mRS >2 Any contra-indication for intravenous thrombolysis (IVT), according to guidelines of the American Heart Association, i.e.: Arterial blood pressure exceeding 185/110 mmHg Blood glucose less than 2.7 or over 22.2 mmol/L Cerebral infarction in the previous 6 weeks with residual neurological deficit or signs of recent infarction on neuro-imaging Serious head trauma in the previous 3 months Major surgery or serious trauma in the previous 2 weeks Gastrointestinal or urinary tract hemorrhage in the previous 3 weeks Previous intracerebral hemorrhage Use of anticoagulant with INR exceeding 1.7 Known thrombocyte count less than 100 x 10^9/L Treatment with direct thrombin or factor X inhibitors Treatment with heparin (APTT exceeds the upper limit of normal value) in the previous 48 hours.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fu-Qiang Guo, M.D.
Phone
+8618981838913
Email
guofuqiang2005@126.com
First Name & Middle Initial & Last Name or Official Title & Degree
Fu-Qiang Guo, M.D.
Phone
M.D.
Email
guofuqiang2005@126.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fu-Qiang Guo, M.D.
Organizational Affiliation
Sichuan Academy of Medical Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
City
Hefei
State/Province
Anhui
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wei Hu, M.D., Ph.D.
Email
andinghu@126.com
Facility Name
Banan Hospital Affiliated to Chongqing Medical University
City
Chongqing
State/Province
Chongqing
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cheng-De Pan, M.D.
Email
28513862@qq.com
Facility Name
Chongqing Sanbo Chang'an Hospital
City
Chongqing
State/Province
Chongqing
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jian-Fang Luan, M.D.
Email
260575540@qq.com
Facility Name
Hechuan District People's Hospital
City
Chongqing
State/Province
Chongqing
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zi-Cheng Hu, M.D.
Email
39128522@qq.com
Facility Name
Liangping District People's Hospital
City
Chongqing
State/Province
Chongqing
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ren-Ming Zhong, M.D.
Email
182423275@qq.com
Facility Name
The First People's Hospital of Liangjiang New Area
City
Chongqing
State/Province
Chongqing
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhi-Hong Zhang, M.D.
Email
31794991@qq.com
Facility Name
Yubei District People's Hospital
City
Chongqing
State/Province
Chongqing
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qing-Lin Liu, M.D.
Email
1559605137@qq.com
Facility Name
The Fifth People's Hospital Affiliated to Southern Medical University
City
Guangzhou
State/Province
Guangdong
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hong-Bo Wang, M.D.
Email
whb7248@sina.com
Facility Name
Qiandongnan Miao and Dong Autonomous Prefecture People's Hospital
City
Kaili
State/Province
Guizhou
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jian Shen, M.D.
Email
15985527337@163.com
Facility Name
Tongren People's Hospital
City
Tongren
State/Province
Guizhou
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bo Wu, M.D.
Email
15185915077@163.com
Facility Name
Qianxinan Buyei and Miao Autonomous Prefecture People's Hospital
City
Xingyi
State/Province
Guizhou
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yao-Yu Tian, M.D.
Email
233128070@qq.com
Facility Name
Nanyang Central Hospital
City
Nanyang
State/Province
Henan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chang-Ming Wen, M.D.
Email
13838729696@sina.com
Facility Name
Zhuzhou Central Hospital
City
Zhuzhou
State/Province
Hunan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Si-Zhi Tang, M.D.
Email
1104698501@qq.com
Facility Name
Bazhong Central Hospital
City
Bazhong
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bo Li, M.D.
Email
bol-1970@163.com
Facility Name
Chengdu Third People's Hospital
City
Chengde
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hua Liu, M.D.
Email
hxliumedidoctor@163.com
Facility Name
Affiliated Hospital of Chengdu Medical College
City
Chengdu
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zheng-Zhou Yuan, M.D.
Email
bibiyou@163.com
Facility Name
Chengdu Fifth People's Hospital
City
Chengdu
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yan Wang, M.D.
Email
17340085006@163.com
Facility Name
Chengdu First People's Hospital
City
Chengdu
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hui Zheng, M.D.
Email
270801870@qq.com
Facility Name
Chengdu Second People's Hospital
City
Chengdu
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jie Shen, M.D.
Email
370375606@qq.com
Facility Name
Chongzhou People's Hospital
City
Chengdu
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
You-Lin Wu, M.D.
Email
suriv007@qq.com
Facility Name
Dayi County People's Hospital
City
Chengdu
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wei-Ping Wang, M.D.
Email
2931784181@qq.com
Facility Name
Western Theater General Hospital
City
Chengdu
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jin Fan, M.D.
Email
fanjin821029@163.com
Facility Name
Deyang People's Hospital
City
Deyang
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hong Chen, M.D.
Email
Chenhong_sc@163.com
Facility Name
Guang'an Central Hospital
City
Guang'an
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jun Liu, M.D.
Email
183169326@qq.com
Facility Name
Guangyuan Central Hospital
City
Guangyuan
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hong Liu, M.D.
Email
xinyuhong80025375@126.com
Facility Name
Guangyuan First People's Hospital
City
Guangyuan
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lan Xiong, M.D.
Email
25037440@qq.com
Facility Name
Affiliated Hospital of Southwest Medical University
City
Luzhou
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jing-Lun Li, M.D.
Email
Lj1031611@163.com
Facility Name
Mianyang 404 Hospital
City
Mianyang
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jun Luo, M.D.
Email
luojunlenovo@163.com
Facility Name
Mianyang Central Hospital
City
Mianyang
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yu-Feng Tang, M.D.
Email
dryufeng@yeah.net
Facility Name
Mianyang Third People's Hospital
City
Mianyang
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xin Zou, M.D.
Email
zou82125@163.com
Facility Name
Affiliated Hospital of North Sichuan Medical College
City
Nanchong
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiang-Rong Sun, M.D.
Email
979841174@qq.com
Facility Name
Langzhong People's Hospital
City
Nanchong
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sheng Feng, M.D.
Email
13890805094@163.com
Facility Name
Nanchong Central Hospital
City
Nanchong
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yi-Fei Ji, M.D.
Email
390684068@qq.com
Facility Name
Yilong County People's Hospital
City
Nanchong
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ming Zhang, M.D.
Email
51237294@qq.com
Facility Name
Neijiang Second People's Hospital
City
Neijiang
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jia-Jun Huang, M.D.
Email
hiaun@163.com
Facility Name
Panzhihua Central Hospital
City
Panzhihua
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dong-Hua Li, M.D.
Email
18782399933@163.com
Facility Name
Suining Central Hospital
City
Suining
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shi-Jie Jiang, M.D.
Email
snjsj2010@163.com
Facility Name
Suining First People's Hospital
City
Suining
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bo Zhang, M.D.
Email
3089837@qq.com
Facility Name
Ya'an People's Hospital
City
Ya'an
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jian Wang, M.D.
Email
wangjian0726@126.com
Facility Name
Yibin First People's Hospital
City
Yibin
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jun Wei, M.D.
Email
461301535@qq.com
Facility Name
Yibin Second People's Hospital
City
Yibin
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qin Liu, M.D.
Email
13002881345@163.com
Facility Name
Zigong First People's Hospital
City
Zigong
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tao Qiu, M.D.
Email
qiutao_zgyyy@163.com
Facility Name
Zigong Third People's Hospital
City
Zigong
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Li Wang, M.D.
Email
DoctorLi_Wang@163.com
Facility Name
Ziyang First People's Hospital
City
Ziyang
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hai-Zhi Guo, M.D.
Email
122189013@qq.com
Facility Name
Kashgar First People's Hospital
City
Kashgar
State/Province
Xinjiang
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qing-Bo Lu, M.D.
Email
53400714@qq.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke

We'll reach out to this number within 24 hrs